Pulmonary Arterial Hypertension Pipeline Summary

• The Global Pulmonary Arterial Hypertension Pipeline is witnessing steady progress, driven by increasing research activities and the development of novel therapeutic candidates across various stages of clinical trials.
• The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.

Request for Unlocking the Sample Page of the "Pulmonary Arterial Hypertension Pipeline"

Key Factors Driving the Growth of Pulmonary Arterial Hypertension Pipeline by DelveInsight

• Increasing Disease Burden and Unmet Medical Needs

The rising prevalence of Pulmonary Arterial Hypertension and the need for more effective long-term therapies are major factors driving pipeline growth. Increasing awareness and earlier diagnosis are also contributing to the demand for advanced treatment options.

• Advancements in Novel Therapeutic Approaches

The pipeline is expanding due to the development of innovative therapies, including prostacyclin pathway agents, endothelin receptor antagonists, soluble guanylate cyclase stimulators, and gene-based treatment approaches aimed at improving patient outcomes.

• Strong Industry Participation

Leading pharmaceutical and biotechnology companies are actively investing in the PAH pipeline, focusing on next-generation therapies and strategic collaborations to strengthen their research and development efforts.

• Growing Clinical Trial Activity

A significant number of candidates are being evaluated across Phase I, Phase II, and Phase III clinical trials, reflecting the increasing momentum in the PAH therapeutic landscape and the potential for new product launches in the coming years.

• Regulatory Support for Rare Diseases

Favorable regulatory pathways, including orphan drug designation and expedited approval programs, are encouraging companies to accelerate the development of novel PAH therapies.

• Increased Research and Development Investments

Continuous investments in cardiovascular research, along with advances in precision medicine and targeted therapies, are further supporting the growth of the Pulmonary Arterial Hypertension pipeline.

DelveInsight’s, “Pulmonary Arterial Hypertension Pipeline Insight, 2026,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension Pipeline Landscape. It covers the Pulmonary Arterial Hypertension Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Arterial Hypertension Therapeutics Assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pulmonary Arterial Hypertension Understanding

Pulmonary Arterial Hypertension Overview

Pulmonary arterial hypertension is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test”, which measures how far an individual can walk in that time period. Pulmonary Arterial Hypertension treatment includes prostaglandins, endothelin receptor antagonists, phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies. 

Explore More Insights on the Report @ Pulmonary Arterial Hypertension Treatment Market Size

Pulmonary Arterial Hypertension Pipeline Report Highlights

The Pulmonary Arterial Hypertension Companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The Pulmonary Arterial Hypertension Therapies under development are focused on novel approaches to treat/improve Pulmonary Arterial Hypertension.

Pulmonary Arterial Hypertension Emerging Drugs Analysis

This segment of the Pulmonary Arterial Hypertension Pipeline Report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand Pulmonary Arterial Hypertension Clinical Trials details, expressive pharmacological action, agreements and collaborations, and the latest Pulmonary Arterial Hypertension news and press releases.

Pulmonary Arterial Hypertension Emerging Drugs

• Sotatercept: Acceleron Pharma

Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.

• LIQ861: Liquidia Technologies

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).

For More Information on the Report @ Pulmonary Arterial Hypertension Prevalence

Pulmonary Arterial Hypertension Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Arterial Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

Major Pulmonary Arterial Hypertension Companies

There are approx. 55+ key companies which are developing the Pulmonary Arterial Hypertension Therapies. The Pulmonary Arterial Hypertension Companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Liquidia Technologies.

Phases

DelveInsight’s Pulmonary Arterial Hypertension Pipeline Report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pulmonary Arterial Hypertension Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Pulmonary Arterial Hypertension Products have been categorized under various ROAs such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Pulmonary Arterial Hypertension Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Arterial Hypertension Clinical Trials Activities

The Pulmonary Arterial Hypertension Pipeline Report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Arterial Hypertension Therapeutic Drugs Companies involved in developing key drugs.

Pulmonary Arterial Hypertension Pipeline Development Activities

The Pulmonary Arterial Hypertension Pipeline Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Arterial Hypertension Drugs.

Pulmonary Arterial Hypertension Pipeline Report Insights

• Pulmonary Arterial Hypertension Pipeline Analysis
• Pulmonary Arterial Hypertension Therapeutic Assessment
• Pulmonary Arterial Hypertension Unmet Needs
• Impact of Pulmonary Arterial Hypertension Drugs

Pulmonary Arterial Hypertension Pipeline Report Assessment

• Pulmonary Arterial Hypertension Pipeline Product Profiles
• Pulmonary Arterial Hypertension Therapeutic Assessment
• Pulmonary Arterial Hypertension Pipeline Assessment
• Inactive Pulmonary Arterial Hypertension Drugs Assessment
• Pulmonary Arterial Hypertension Unmet Needs

Key Questions Answered in the Pulmonary Arterial Hypertension Pipeline Report

Current Pulmonary Arterial Hypertension Treatment Scenario and Emerging Therapies:

• How many companies are developing Pulmonary Arterial Hypertension Drugs?
• How many Pulmonary Arterial Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Arterial Hypertension?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

Stay updated with us for Recent Articles

• WINREVAIR Approval for Pulmonary Arterial Hypertension Treatment: Is It A Game-Changer for Merck?
• New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Domain
• Pulmonary Arterial Hypertension Therapies
• Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension
• Pulmonary Arterial Hypertension Market Infographics
• Pulmonary Arterial Hypertension Newsletter
• New DelveInsight Blogs